Show simple item record

dc.contributor.authorBarbazán García, Jorge
dc.contributor.authorMuinelo Romay , Laura
dc.contributor.authorVieito Villar, María 
dc.contributor.authorCandamio Folgar, Sonia 
dc.contributor.authorDíaz-López, A.
dc.contributor.authorCano, A.
dc.contributor.authorGómez-Tato, A.
dc.contributor.authorCasares de Cal, M.e L
dc.contributor.authorAbal, M.
dc.contributor.authorLópez López, Rafael 
dc.date.accessioned2017-06-07T07:15:55Z
dc.date.available2017-06-07T07:15:55Z
dc.date.issued2014
dc.identifier.issn0020-7136
dc.identifier.urihttp://hdl.handle.net/20.500.11940/4499
dc.description.abstractCirculating tumor cells (CTCs), proposed as major players in cancer dissemination, have demonstrated clinical prognostic significance in several cancer types. However, their predictive value remains unclear. Here we evaluated the clinical utility of six CTC markers (tissue specific and epithelial to mesenchymal transition transcripts) both as prognostic and predictive tools in metastatic colorectal cancer (mCRC) patients. CTCs were immunoisolated from blood in 50 mCRC patients at baseline and at 4 and 16 weeks after treatment onset. Expression levels of GAPDH, VIL1, CLU, TIMP1, LOXL3 and ZEB2 were determined by qualitative polymerase chain reaction and normalized to the unspecific cell isolation marker CD45. At baseline, median progression-free survival (PFS) and overall survival (OS) for patients with high CTC markers were 6.3 and 12.7 months, respectively, versus 12.7 and 24.2 for patients with low CTC markers (PFS; p = 0.0003; OS; p = 0.044). Concerning response to therapy, PFS and OS for patients with increased CTC markers along treatment were, respectively, 6.6 and 13.1 months, compared with 12.7 and 24.3 for patients presenting CTC markers reduction (PFS; p = 0.004; OS; p = 0.007). Of note, CTC markers identified therapy-refractory patients not detected by standard image techniques. Patients with increased CTC markers along treatment, but classified as responders by computed tomography, showed significantly shorter survival times (PFS: 7.8 vs. 13.2; OS: 14.4 vs. 24.4; months). In conclusion, we have generated a CTC marker panel for prognosis evaluation and the identification of patients benefiting or not from therapy in mCRC. Our methodology efficiently classified patients earlier than routine computed tomography and from a minimally invasive liquid biopsy.
dc.language.isoeng
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBevacizumab
dc.subject.meshBiomarkers, Tumors
dc.subject.meshCamptothecin
dc.subject.meshCapecitabine
dc.subject.meshCetuximab
dc.subject.meshColorectal Neoplasms
dc.subject.meshDeoxycytidine
dc.subject.meshEpithelial-Mesenchymal Transition
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshIrinotecan
dc.subject.meshLiver Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshNeoplastic Cells, Circulating
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshOxaliplatin
dc.subject.meshPrognosis
dc.subject.meshSurvival Rate
dc.titleA multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer
dc.typeArtigoes
dc.authorsophosBarbazán, J.
dc.authorsophosMuinelo-Romay, L.
dc.authorsophosVieito, M.
dc.authorsophosCandamio, S.
dc.authorsophosDíaz-López, A.
dc.authorsophosCano, A.
dc.authorsophosGómez-Tato, A.
dc.authorsophosCasares de Cal, M.e L
dc.authorsophosAbal, M.
dc.authorsophosLópez-López, R.
dc.identifier.doi10.1002/ijc.28910
dc.identifier.isi342811800015
dc.identifier.pmid24752533
dc.identifier.sophos14568
dc.issue.number11
dc.journal.titleINTERNATIONAL JOURNAL OF CANCER
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initial2633
dc.page.final43
dc.rights.accessRightsopenAccess
dc.typesophosArtículo Original
dc.volume.number135


Files in this item

This item appears in the following Collection(s)

Show simple item record